Literature DB >> 24553294

Use of vaccines as probes to define disease burden.

Daniel R Feikin1, J Anthony G Scott2, Bradford D Gessner3.   

Abstract

Vaccine probe studies have emerged in the past 15 years as a useful way to characterise disease. By contrast, traditional studies of vaccines focus on defining the vaccine effectiveness or efficacy. The underlying basis for the vaccine probe approach is that the difference in disease burden between vaccinated and unvaccinated individuals can be ascribed to the vaccine-specific pathogen. Vaccine probe studies can increase understanding of a vaccine's public health value. For instance, even when a vaccine has a seemingly low efficacy, a high baseline disease incidence can lead to a large vaccine-preventable disease burden and thus that population-based vaccine introduction would be justified. So far, vaccines have been used as probes to characterise disease syndromes caused by Haemophilus influenzae type b, pneumococcus, rotavirus, and early infant influenza. However, vaccine probe studies have enormous potential and could be used more widely in epidemiology, for example, to define the vaccine-preventable burden of malaria, typhoid, paediatric influenza, and dengue, and to identify causal interactions between different pathogens.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24553294      PMCID: PMC4682543          DOI: 10.1016/S0140-6736(13)61682-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  51 in total

1.  Creation of a research program to determine the etiology and epidemiology of acute respiratory tract infection among children in developing countries.

Authors:  J R Bale
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

2.  Use of vaccine trials to estimate burden of disease.

Authors:  E Kim Mulholland
Journal:  J Health Popul Nutr       Date:  2004-09       Impact factor: 2.000

3.  Aetiology of pneumonia in children in Goroka Hospital, Papua New Guinea.

Authors:  F Shann; M Gratten; S Germer; V Linnemann; D Hazlett; R Payne
Journal:  Lancet       Date:  1984-09-08       Impact factor: 79.321

4.  Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial.

Authors:  George E Armah; Samba O Sow; Robert F Breiman; Michael J Dallas; Milagritos D Tapia; Daniel R Feikin; Fred N Binka; A Duncan Steele; Kayla F Laserson; Nana A Ansah; Myron M Levine; Kristen Lewis; Michele L Coia; Margaret Attah-Poku; Joel Ojwando; Stephen B Rivers; John C Victor; Geoffrey Nyambane; Abraham Hodgson; Florian Schödel; Max Ciarlet; Kathleen M Neuzil
Journal:  Lancet       Date:  2010-08-06       Impact factor: 79.321

5.  Efficacy of a pneumococcal conjugate vaccine against acute otitis media.

Authors:  J Eskola; T Kilpi; A Palmu; J Jokinen; J Haapakoski; E Herva; A Takala; H Käyhty; P Karma; R Kohberger; G Siber; P H Mäkelä
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

6.  Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial.

Authors:  Bradford D Gessner; Agustinus Sutanto; Mary Linehan; I Gusti Gede Djelantik; Tracy Fletcher; I Komang Gerudug; David Mercer; Vanda Moniaga; Lawrence H Moulton; Lawrence H Moulton; Kim Mulholland; Carib Nelson; Soewignjo Soemohardjo; Mark Steinhoff; Anton Widjaya; Philippe Stoeckel; James Maynard; Soemarjati Arjoso
Journal:  Lancet       Date:  2005 Jan 1-7       Impact factor: 79.321

7.  Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections.

Authors:  R Lagos; I Horwitz; J Toro; O San Martin; P Abrego; C Bustamante; S S Wasserman; O S Levine; M M Levine
Journal:  Pediatr Infect Dis J       Date:  1996-03       Impact factor: 2.129

8.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245

9.  Efficacy and safety of seven-valent conjugate pneumococcal vaccine in American Indian children: group randomised trial.

Authors:  Katherine L O'Brien; Lawrence H Moulton; Raymond Reid; Robert Weatherholtz; Jane Oski; Laura Brown; Gaurav Kumar; Alan Parkinson; Diana Hu; Jill Hackell; Ih Chang; Robert Kohberger; George Siber; Mathuram Santosham
Journal:  Lancet       Date:  2003-08-02       Impact factor: 79.321

10.  A role for Streptococcus pneumoniae in virus-associated pneumonia.

Authors:  Shabir A Madhi; Keith P Klugman
Journal:  Nat Med       Date:  2004-07-11       Impact factor: 53.440

View more
  41 in total

1.  Prevention of invasive pneumococcal diseases: beyond cultures.

Authors:  Carlos G Grijalva; Marie R Griffin
Journal:  Lancet Respir Med       Date:  2014-08-07       Impact factor: 30.700

Review 2.  The Antibody-Secreting Cell Response to Infection: Kinetics and Clinical Applications.

Authors:  Michael J Carter; Ruth M Mitchell; Patrick M Meyer Sauteur; Dominic F Kelly; Johannes Trück
Journal:  Front Immunol       Date:  2017-06-01       Impact factor: 7.561

3.  Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet Infect Dis       Date:  2017-08-23       Impact factor: 25.071

4.  Uses of pathogen detection data to estimate vaccine direct effects in case-control studies.

Authors:  Joseph A Lewnard
Journal:  J R Soc Interface       Date:  2020-08-12       Impact factor: 4.118

Review 5.  The case for a typhoid vaccine probe study and overview of design elements.

Authors:  Bradford D Gessner; M Elizabeth Halloran; Imran Khan
Journal:  Vaccine       Date:  2015-04-23       Impact factor: 3.641

Review 6.  Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy.

Authors:  Bradford D Gessner; Daniel R Feikin
Journal:  Vaccine       Date:  2014-04-13       Impact factor: 3.641

7.  Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

8.  Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors: 
Journal:  Lancet       Date:  2014-12-18       Impact factor: 79.321

9.  Building the case for wider use of typhoid vaccines.

Authors:  John A Crump
Journal:  Vaccine       Date:  2015-04-21       Impact factor: 3.641

10.  Influenza epidemiology and immunization during pregnancy: Final report of a World Health Organization working group.

Authors:  Deshayne B Fell; Eduardo Azziz-Baumgartner; Michael G Baker; Maneesh Batra; Julien Beauté; Philippe Beutels; Niranjan Bhat; Zulfiqar A Bhutta; Cheryl Cohen; Bremen De Mucio; Bradford D Gessner; Michael G Gravett; Mark A Katz; Marian Knight; Vernon J Lee; Mark Loeb; Johannes M Luteijn; Helen Marshall; Harish Nair; Kevin Pottie; Rehana A Salam; David A Savitz; Suzanne J Serruya; Becky Skidmore; Justin R Ortiz
Journal:  Vaccine       Date:  2017-09-01       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.